Overview

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Status:
Completed

Trial end date:
2018-05-08

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection and decompensated cirrhosis.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Molecular Mechanisms of Pharmacological Action
Ribavirin
Sofosbuvir
Sofosbuvir-velpatasvir drug combination